 |
|||||
| The Executive Officers |
|||||
| Executive Officers | |||||
| Richard J. Freer, Ph.D. Chairman of the Board and COO |
Robert B. Harris, Ph.D. President & CEO |
||||
| Thomas R. Reynolds Executive Vice President, Science & Technology and Secretary |
James H. Brennan, MBA Controller |
||||
| Directors |
|||||
| Richard J. Freer, Ph.D. Chairman of the Board and Chief Operating Officer |
Robert B. Harris, Ph.D. President & CEO |
||||
| Thomas R. Reynolds
Executive Vice President, Science & Technology and Secretary |
Mr. Peter Einselen Broker, Anderson-Strudwick Investment Corp. |
||||
| Donald A. McAfee, Ph.D. Chief Technical Officer, Aderis Pharmaceuticals, Inc. |
Mr. Samuel P. Sears,
Jr. Attorney, Business Development |
||||
|
Mr. James Causey President and CEO Sabot Publishing, Co. |
Gerald P. Krueger, Ph.D. Principal Scientist The Wexford Group International |
||||
Overview of CBI CBI was founded in 1992 by four experienced research scientists to provide sophisticated research and development support services on a contract basis to the biotechnology industry. CBI's customers consist of private companies, academic institutions, and government agencies, all of which use biological processes to develop products for health care, agricultural, and other purposes. CBI has developed a strong reputation as a leading provider of biotechnology research and development analytical services. Providing a wide range of services is an important element of our strategy. There are few major competitors which offer integrated DNA/RNA and protein/peptide technologies, and none that offer these technologies combined with sophisticated biophysical techniques, such as calorimetery, spectroscopy, and mass spectral analysis. Thus, CBI can provide "one stop shopping" for biotechnology services. |
|||||
|
|||||
